全文获取类型
收费全文 | 221919篇 |
免费 | 21059篇 |
国内免费 | 15525篇 |
专业分类
耳鼻咽喉 | 1968篇 |
儿科学 | 2215篇 |
妇产科学 | 2987篇 |
基础医学 | 26710篇 |
口腔科学 | 3715篇 |
临床医学 | 31104篇 |
内科学 | 33224篇 |
皮肤病学 | 2242篇 |
神经病学 | 12491篇 |
特种医学 | 8370篇 |
外国民族医学 | 139篇 |
外科学 | 22052篇 |
综合类 | 35959篇 |
现状与发展 | 57篇 |
一般理论 | 19篇 |
预防医学 | 13301篇 |
眼科学 | 6732篇 |
药学 | 22999篇 |
213篇 | |
中国医学 | 12548篇 |
肿瘤学 | 19458篇 |
出版年
2024年 | 725篇 |
2023年 | 3621篇 |
2022年 | 9343篇 |
2021年 | 11708篇 |
2020年 | 8767篇 |
2019年 | 7643篇 |
2018年 | 8170篇 |
2017年 | 7217篇 |
2016年 | 6739篇 |
2015年 | 10405篇 |
2014年 | 12691篇 |
2013年 | 10837篇 |
2012年 | 16225篇 |
2011年 | 18121篇 |
2010年 | 10653篇 |
2009年 | 8299篇 |
2008年 | 11213篇 |
2007年 | 11191篇 |
2006年 | 11357篇 |
2005年 | 11399篇 |
2004年 | 7046篇 |
2003年 | 6652篇 |
2002年 | 5551篇 |
2001年 | 4977篇 |
2000年 | 5380篇 |
1999年 | 5743篇 |
1998年 | 3547篇 |
1997年 | 3514篇 |
1996年 | 2832篇 |
1995年 | 2621篇 |
1994年 | 2145篇 |
1993年 | 1381篇 |
1992年 | 1899篇 |
1991年 | 1599篇 |
1990年 | 1293篇 |
1989年 | 1093篇 |
1988年 | 1018篇 |
1987年 | 894篇 |
1986年 | 729篇 |
1985年 | 528篇 |
1984年 | 336篇 |
1983年 | 242篇 |
1982年 | 149篇 |
1981年 | 145篇 |
1980年 | 111篇 |
1979年 | 142篇 |
1978年 | 49篇 |
1977年 | 53篇 |
1975年 | 57篇 |
1974年 | 56篇 |
排序方式: 共有10000条查询结果,搜索用时 11 毫秒
91.
92.
Xiaoxuan Liu Ameenat L. Solebo Livia Faes Sophie Beese Tasanee Braithwaite Matthew E. Round 《Ocular immunology and inflammation》2020,28(6):898-907
ABSTRACT
Purpose
New instrument-based techniques for anterior chamber (AC) cell counting can offer automation and objectivity above clinician assessment. This review aims to identify such instruments and its correlation with clinician estimates. 相似文献93.
This paper reviews the published literature on a group of developmental disorders of the retina and retinal pigment epithelium which result in focal abnormalities in one or both eyes. They are often asymptomatic, found on routine examination and are generally non-progressive. Some are associated with other systemic abnormalities.Subject terms: Retinal diseases, Eye abnormalities 相似文献
94.
95.
96.
97.
S. Xing X. Zhang J. H. Liu X. Huang P. Zhou 《Clinical and experimental immunology》2019,195(1):121-131
Recent experimental strategies to reduce graft-versus-host disease (GVHD) have focused largely on modifying innate immunity. Toll-like receptor (TLR)-driven myeloid differentiation primary response 88 (MyD88)-dependent signalling pathways that initiate adaptive immune function are also critical for the pathogenesis of GVHD. This study aimed to delineate the role of host MyD88 in the development of acute GVHD following fully major histocompatibility complex-mismatched allogeneic bone marrow transplantation (BMT). When myeloablated BALB/c MyD88 knock-out recipients were transplanted with C57BL/6 (B6) donor cells, they developed significantly more severe GVHD than wild-type (WT) BALB/c hosts. The increased morbidity and mortality in MyD88–/– mice correlated with increased serum levels of lipopolysaccharide and elevated inflammatory cytokines in GVHD target organs. Additionally, MyD88 deficiency in BMT recipients led to increased donor T cell expansion and more donor CD11c+ cell intestinal infiltration with apoptotic cells but reduced proliferation of intestinal epithelial cells compared with that in WT BMT recipients. Decreased expression of tight junction mRNA in epithelial cells of MyD88–/– mice suggested that MyD88 contributes to intestinal integrity. Cox-2 expression in the GVHD-targeted organs of WT mice is increased upon GVHD induction, but this enhanced expression was obviously inhibited by MyD88 deficiency. The present findings demonstrate an unexpected role for host MyD88 in preventing GVHD after allogeneic BMT. 相似文献
98.
BackgroundArtificial insemination with the husband’s semen (AIH) is an economical and noninvasive method of infertility treatment. However, AIH’s pregnancy rate is much lower than in vitro fertilization (IVF) as its multiple and complex uncertainty factors. Semen quality has been one of the main factors which affect the pregnancy outcome of AIH.MethodsThe relevant parameters of 1,142 AIH cycles were retrospectively studied, including the general parameters and the semen quality parameters among clinical pregnancy, biochemical pregnancy, non-pregnancy group, age, infertility duration, infertility type, body mass index (BMI), cycle count, morphology in previously semen examination, and semen quality parameters on the day of AIH.ResultsThe statistically significant difference was only found on processed total non-forward and non-motile sperm count (N-TFMSC). The mean processed N-TFMSC in the biochemical pregnancy group was 6.37±4.27 million, significantly higher than the other two groups (vs. 4.40±3.15 million or vs. 4.48±3.60 million, P<0.05). The study was then divided into two groups according to processed N-TFMSC, Group 1 ≤5.0 million, and Group 2 >5.0 million. A statistical increase in biochemical pregnancy rate was observed when the processed N-TFMSC was >5.0 million (2.72% vs. 0.90%).ConclusionsProcessed N-TFMSC may be one of the independent factors on AIH’s outcome; it should be given equal attention the same as processed total forward motile sperm count (TFMSC). 相似文献
99.
100.
Wen Wang Yanmei Liu Chuan Yu Jing Tan Weiyi Xiong Duo Dong 《Expert opinion on drug safety》2020,19(3):339-347
ABSTRACTObjectives: Limited evidence has suggested that cefoperazone-sulbactam causes coagulation disorders and bleeding.Methods: The authors conducted a retrospective study to compare patients receiving cefoperazone-sulbactam versus those treated with cefoperazone-tazobactam or ceftazidime. Propensity-score matching was used to explore whether treatment with cefoperazone-sulbactam increased the risk of prothrombin time (PT) prolongation, coagulation disorders, and bleeding, or decreased platelets (PLT).Results: The cohort included 23,242 patients. Among patients receiving cefoperazone-sulbactam, the risk of PT prolongation, coagulation disorders, decreased PLT, and bleeding was 5.3%, 9.2%, 15.7%, and 4.2%, respectively. Propensity-score matching analyses suggested that cefoperazone-sulbactam increased the risk of PT prolongation (aOR 2.26, 95% CI 1.61–3.18), coagulation disorders (aOR 1.81, 95% CI 1.43–2.30), and decreased PLT (aOR 1.46, 95% CI 1.25–1.72), but not increase bleeding (aOR 1.05, 95% CI 0.79–1.40) compared with ceftazidime. Patients receiving cefoperazone-sulbactam had higher risk of PT prolongation (aOR 1.53, 95% CI 1.11–2.10), coagulation disorders (aOR 1.53, 95% CI 1.21–1.95), but not decreased PLT (aOR 0.93, 95% CI 0.81–1.07) or bleeding (aOR 1.11, 95% CI 0.87–1.42), compared with those receiving cefoperazone-tazobactam.Conclusion: Cefoperazone-sulbactam may be associated with a higher risk of PT prolongation and coagulation disorders compared with cefoperazone-tazobactam and ceftazidime. 相似文献